

Special Issue

Ibrutinib in Chronic Lymphocytic Leukemia

Message from the Guest Editor

Introduction of Bruton Tyrosine kinase (BTK) inhibitors in the clinical practice has deeply altered the treatment paradigm of Chronic Lymphocytic Leukemia (CLL) patients. In particular, ibrutinib is the first BTK inhibitor used in the treatment of CLL that is able to bind covalently to cysteine residue (C481) in the ATP-binding domain of the BTK kinase leading to inhibition of its enzymatic activity. Inhibition of BTK prevents downstream activation of the BCR pathway affecting cell growth, proliferation, homing and survival of the leukemic B cells. Although ibrutinib has shown excellent effects on CLL cell component inducing mobilization of lymphocytes from tissue into the blood with the consequent cell death, recently different studies have demonstrated the on-target effects on off-tumor cells related to tumor microenvironment. This Special Issue aims to summarize the current knowledge and cutting-edge research on BTK inhibitors in CLL.

Guest Editor

Dr. Stefania Fiorcari

Department of Oncology and Hematology, Division of Immuno-Hematology and Trasfusion Medicine, Azienda Ospedaliero Universitaria, Policlinico of Modena, via Del Pozzo 71, 41124 Modena, Italy

Deadline for manuscript submissions

closed (25 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/172818

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)